Interneuron Pharmaceuticals Inc. (NASDAQ:IPIC) reportedThursday the massed results of its extensive, internationalPhase III clinical trials on the anti-obesity compounddexfenfluramine.
Charles Casamento, chief executive officer of the Lexington,Mass., company, summarized the trail results at Cowen & Co.'smeeting in San Francisco. Of the 17 double-blinded, controlledtrials on the drug, there were "statistically significantdifferences between the treatment groups and the placebos inall but one trial," Casamento said. Both groups of patients wereon the same dietary regime; those taking the drug lost fromseven to 19 pounds more than the placebo group. Interneuronplans to file its investigational new drug (IND) application ondexfenfluramine next March.
(c) 1997 American Health Consultants. All rights reserved.